



# 8  
Cinda R  
D. Bryce  
7/13/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: 09/316,226 Art Unit: 3762

Filed: May 21, 1999 Examiner: W. Noggle

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT**

Sir:

Responsive to the Office Action mailed February 14, 2000, please amend the application as follows. A Petition for an Extension of Time for one month, up to and including June 14, 2000, and the appropriate fee for a small entity, are enclosed with this response.

**In the Claims**

1. (amended) A method for inducing an immune response against transformed, infected or diseased tissue in a patient comprising  
  
removing [only components present] soluble cytokine receptor molecules selected from the group consisting of soluble tissue necrosis factor receptor-1 (“sTNFR-1”), soluble tissue necrosis factor receptor-2 (“sTNFR-2”), soluble interleukin-2 receptor (“sIL-2R”), soluble interleukin-1 receptor (“sIL-1R”), soluble interleukin-6 receptor (“sIL-6R”), and soluble interferon-gamma receptor (“sIFN-gammaR”) in the blood of the patient having a molecular weight of 120,000 daltons or less, until the transformed, infected, or diseased tissue is reduced in amount.

5. (amended) [The] A method [of claim 1 further comprising] for treating [the tissue] a patient with tumors by removing from the blood the components having a molecular weight of

06/27/2000 JADD01 00000001 012507 09316226

01 FC:203

27.00 CH

B

20

a